10x Genomics Q4 2023 Adj EPS $(0.24) Beats $(0.36) Estimate, Sales $183.98M Beat $182.80M Estimate
Portfolio Pulse from Benzinga Newsdesk
10x Genomics (NASDAQ:TXG) reported Q4 2023 adjusted EPS of $(0.24), surpassing the $(0.36) estimate, with sales of $183.98M exceeding the $182.80M forecast. This represents a 17.76% increase in sales compared to the same period last year.
February 15, 2024 | 9:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
10x Genomics reported a better-than-expected Q4 2023 with adjusted EPS of $(0.24) and sales of $183.98M, beating estimates and showing a significant year-over-year growth.
The positive earnings surprise and sales beat by 10x Genomics are likely to instill investor confidence and could lead to a short-term uptick in TXG's stock price. The significant year-over-year sales growth further underscores the company's strong performance and potential for future growth.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100